Effect of the calcium antagonist nicardipine hydrochloride on glucose tolerance and insulin secretion.
The calcium antagonist nicardipine was administered to 42 patients at a dose of 60 or 120 mg/day for an average of 7.8 weeks to determine its effects on glucose tolerance and insulin secretion. Glucose tolerance and immunoreactive insulin levels were essentially unchanged by nicardipine regardless of the preexisting level of glucose tolerance. Mean systolic and diastolic blood pressures decreased in all patients. Concentrations of triglycerides decreased and high-density lipoprotein cholesterol levels increased significantly (p less than 0.05) in association with nicardipine administration. Therefore it is concluded that, regardless of the preexisting level of glucose tolerance, nicardipine exerted hypotensive effects without significant adverse effects on glucose tolerance or insulin secretion.
Kihara
A
A
Department of Internal Medicine, School of Allied Health Professions, Sapporo Medical College, Japan.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001786:Blood Glucose / Q000378:metabolism*; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D008297:Male; D008875:Middle Aged; D009529:Nicardipine / Q000494:pharmacology*
D001786:Blood Glucose; D007328:Insulin; D009529:Nicardipine